Skip to main content Skip to page footer

Ihre Suche

Logo des NCT Heidelberg Logo des NCT Heidelberg
 
Eingabe löschen
 
Bitte klicken Sie nach Auswahl der Kategorie auf „Suchen“.
Eingabe löschen
469 Treffer:
Suchergebnisse 61 bis 70 von 469
61. A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors *Nur für NSCLS offen*
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
AMG 193  
62. A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
SGNDV-004  
63. A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
GOBLET  
64. A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
GOBLET  
65. A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
GOBLET  
66. A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
GOBLET  
67. A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
SGNDV-004  
68. Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors.
NCT Heidelberg » Ihre Suche
 
Datum: 2025-10-23
IMA203-101  
69. 251013_WINKLER_EVA_Publication_record.docx
 
Datum: 2025-10-14
… and ultimate human…  
70. Pinktober - Gemeinsam gegen Brustkrebs! Königin Silvia von Schweden übernimmt symbolische Schirmherrschaft
 
Datum: 2025-10-02
… Basketballteam der MLP…  
Suchergebnisse 61 bis 70 von 469